PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 902 participants.

Also called NCT02171065

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose basic science
Phase
Not applicable
Enrolled
  • 902 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02171065
Other papers using this trial's data
  • Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque Journal of the American College of Cardiology, 2020-11-17 DOI, PubMed 33069847
  • Relationships of hsCRP to High-Risk Vulnerable Plaque After NSTEMI: Insights From the PROSPECT II Trial JACC. Cardiovascular interventions, 2025-05-26 DOI, PubMed 40272345

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02171065. Randomized; no masking; primary purpose basic science. Start 2014-06 (actual); primary completion 2020-05 (actual). Results posted on 2021-08-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.
Acronym
P2
Condition
Acute Coronary Syndrome (ACS)
Intervention (Device)
sham
Intervention (Device)
ABSORB BVS
Lead sponsor
Uppsala University (class: other)
Collaborator
Abbott Medical Devices (class: industry)
Collaborator
Infraredx (class: industry)
Collaborator
The Medicines Company (class: industry)

Record details

Record id
cardio:ct-nct02171065
Content hash
7322fe93f66cb83ff669dcfbb7fccc06ee0c2c381aeda48e41436b40e6b1cca0